Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 9.52 is in line with its 5-year average of 9.19, near the low end of its 5-year range (2.40–33.20).
As of the fiscal period ended Tuesday, June 30, 2026. 22.48% above its 12-month average of 7.78.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.52.
QUICK RATIO (ACID-TEST)
9.52
QUICK RATIO (ACID-TEST) AVG TTM
7.78
QUICK RATIO (ACID-TEST) AVG 3Y
6.80
QUICK RATIO (ACID-TEST) AVG 5Y
9.19
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+22.48%
CURRENT VS 3Y AVG
+40.11%
CURRENT VS 5Y AVG
+3.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 563 covered companies
CURRENT VS SECTOR MEDIAN
+218.54%
vs the sector median at left
Monte Rosa Therapeutics, Inc.
Market Cap
$854.51M
Quick Ratio (Acid-Test)
9.52
TTM Avg
7.78
3Y Avg
6.80
5Y Avg
9.19
Market Cap
$853.77M
Quick Ratio (Acid-Test)
7.96
TTM Avg
6.81
3Y Avg
6.62
5Y Avg
6.62
Market Cap
$875.38M
Quick Ratio (Acid-Test)
16.16
TTM Avg
3.88
3Y Avg
3.97
5Y Avg
4.50
Market Cap
$833.10M
Quick Ratio (Acid-Test)
14.93
TTM Avg
20.63
3Y Avg
16.30
5Y Avg
22.70
Market Cap
$882.01M
Quick Ratio (Acid-Test)
81.42
TTM Avg
11.94
3Y Avg
8.59
5Y Avg
10.34
Market Cap
$812.73M
Quick Ratio (Acid-Test)
3.15
TTM Avg
4.21
3Y Avg
3.84
5Y Avg
4.13
Market Cap
$817.21M
Quick Ratio (Acid-Test)
3.86
TTM Avg
4.02
3Y Avg
3.56
5Y Avg
3.80
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $854.51M | 9.52 | 7.78 | 6.80 | 9.19 |
| Beta Bionics, Inc. (BBNX)vs › | $853.77M | 7.96 | 6.81 | 6.62 | 6.62 |
| Apnimed, Inc. (APMD)vs › | $824.34M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $875.38M | 16.16 | 3.88 | 3.97 | 4.50 |
| Jade Biosciences, Inc. (JBIO)vs › | $833.10M | 14.93 | 20.63 | 16.30 | 22.70 |
| Alumis Inc. (ALMS)vs › | $830.70M | 6.74 | 5.17 | 5.15 | 5.15 |
| Arbutus Biopharma Corp (ABUS)vs › | $882.01M | 81.42 | 11.94 | 8.59 | 10.34 |
| Ardelyx, Inc. (ARDX)vs › | $812.73M | 3.15 | 4.21 | 3.84 | 4.13 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $817.21M | 3.86 | 4.02 | 3.56 | 3.80 |
| InMode Ltd. (INMD)vs › | $809.62M | 7.28 | 9.00 | 9.42 | 9.03 |
Quick Ratio
9.52
Excludes inventory
Current Ratio
9.52
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 9.52 |
| 2026-03-31 | 9.54 |
| 2025-12-31 | 6.12 |
| 2025-09-30 | 6.54 |
| 2025-06-30 | 7.16 |
| 2025-03-31 | 5.61 |
| 2024-12-31 | 2.40 |
| 2024-09-30 | 6.03 |
| 2024-06-30 | 6.56 |
| 2024-03-31 | 4.82 |
| 2023-12-31 | 5.07 |
| 2023-09-30 | 8.09 |
| 2023-06-30 | 10.90 |
| 2023-03-31 | 11.73 |
| 2022-12-31 | 10.79 |
| 2022-09-30 | 13.55 |
| 2022-06-30 | 20.11 |
| 2022-03-31 | 25.65 |
| 2021-12-31 | 20.96 |
| 2021-09-30 | 29.08 |
| 2021-06-30 | 33.20 |
| 2021-03-31 | 18.89 |
| 2020-12-31 | 1.49 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
